ArticleTrials2024

Treat-to-target fixed dose rituximab retreatment versus fixed interval retreatment with disease activity-guided rituximab dose optimisation for patients with rheumatoid arthritis: study protocol for a multicentre randomised controlled superiority trial focusing on long-term disease impact (RITUXERA).

Elias De Meyst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.